派林生物: 关于筹划公司控制权变更事项进展暨复牌公告

Group 1 - The company is planning a change in control, with the controlling shareholder, Shengbang Yinghao Investment Partnership, intending to transfer 21.03% of its shares to China National Pharmaceutical Group [1][2] - The actual controller will shift from the Shaanxi Provincial Government's State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group if the transaction proceeds successfully [1][2] - The company's stock was suspended from trading on June 6, 2025, and is set to resume trading on June 10, 2025, to ensure liquidity and protect investor interests [2][3] Group 2 - A framework agreement for the acquisition has been signed, but the transaction is still subject to due diligence and regulatory approvals, which introduces uncertainty regarding its completion [2] - The company will continue to fulfill its information disclosure obligations in accordance with legal regulations following the resumption of trading [2]